ClinicalTrials.gg
CompletedNCT03548220Updated May 24, 2022Results posted

A Study to Evaluate Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD)

A Phase 3 interventional study of Placebo and AG-348 in Pyruvate Kinase Deficiency and Anemia, Hemolytic, sponsored by Agios Pharmaceuticals, Inc.. Completed at 46 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-24.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Anemia, Hemolytic with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. Anemia, Hemolytic · United States.

Enrollment
6th of 26
80 · median 47
Started
2018
with 2 others
Phase 3
4 of 35
none open now
Registered
18th of 35
by date
Lead sponsor
4 of 35
Agios Pharmaceuticals, Inc.

Among the 35 studies in Anemia, Hemolytic with a site in United States, this one is the 6th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2018, is one of 4 in phase 3, and was the 18th registered.

Anemia, Hemolytic

56 studies on the registry are indexed under Anemia, Hemolytic; 16 are open to participants now.

Browse Anemia, Hemolytic studies →

Open to participants now

8 of the 35 studies in Anemia, Hemolytic with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Anemia, Hemolytic studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 6 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Anemia, Hemolytic with a site in United States, or all of them as a file.
02

Study summary

Study AG348-C-006 evaluated the efficacy and safety of orally administered AG-348 as compared with placebo in participants with pyruvate kinase (PK) deficiency, who were not regularly receiving blood transfusions. Participants were randomized 1:1 to receive either AG-348 or a matching placebo.

03

Conditions studied

  • Pyruvate Kinase Deficiency
  • Anemia, Hemolytic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ;
  • Male or female, aged 18 years or older;
  • Documented clinical laboratory confirmation of pyruvate kinase (PK) deficiency, defined as documented presence of at least 2 mutant alleles in the PKLR gene, of which at least 1 is a missense mutation;
  • (Hb) concentration less than or equal to 10.0 grams per deciliter (g/dL) regardless of gender (average of at least 2 Hb measurements [separated by a minimum of 7 days] during the Screening Period)
  • Considered not regularly transfused, defined as having had no more than 4 transfusion episodes in the 12-month period up to the first day of study treatment and no transfusions in the 3 months prior to the first day of study treatment;
  • Received at least 0.8 mg oral folic acid daily for at least 21 days prior to the first dose of study treatment, to be continued daily during study participation.
  • Adequate organ function;
  • Women of , have a negative serum pregnancy test;
  • For women of reproductive potential as well as men with partners who are women of reproductive potential, be abstinent as part of their usual lifestyle, or agree to use 2 forms of , 1 of which must be considered highly effective, from the time of giving informed consent, during the study, and for 28 days following the last dose of study treatment for women and 90 days for men following the last dose of study treatment;
  • Willing to comply with all study procedures for the duration of the study;

Exclusion criteria

Exclusion Criteria:

  • Homozygous for the R479H mutation or have 2 non-missense mutations, without the presence of another missense mutation, in the PKLR gene;
  • Significant medical condition that confers an unacceptable risk to participating in the study, and/or that could confound the interpretation of the study data;
  • Splenectomy scheduled during the study treatment period or have undergone splenectomy within 12 months prior to signing ;
  • Currently enrolled in another therapeutic clinical trial involving ongoing therapy with any or marketed product or placebo. Prior and subsequent participation in the PK Deficiency Natural History Study (NHS) (NCT02053480) or PK Deficiency Registry is permitted however, concurrent participation is not; participants enrolling in this current study will be expected to temporarily suspend participation in the NHS or Registry;
  • Exposure to any investigational drug, device, or procedure within 3 months prior to the first dose of study treatment;
  • Prior treatment with a pyruvate kinase activator;
  • Prior bone marrow or stem cell transplant;
  • Currently pregnant or breastfeeding;
  • History of major surgery within 6 months of signing informed consent;
  • Currently receiving medications that are strong inhibitors of cytochrome P450 (CYP)3A4, strong inducers of , strong inhibitors of P-glycoprotein (P-gp), or digoxin (a P-gp sensitive substrate medication) that have not been stopped for a duration of at least 5 days or a timeframe equivalent to 5 half-lives (whichever is longer) prior to the first dose of study treatment;
  • Currently receiving hematopoietic stimulating agents that have not been stopped for a duration of at least 28 days prior to the first dose of study treatment;
  • History of allergy to sulfonamides if characterized by acute hemolytic anemia, drug induced liver injury, anaphylaxis, rash of erythema multiforme type or Stevens-Johnson syndrome, cholestatic hepatitis, or other serious clinical manifestations;
  • History of allergy to AG-348 or its ;
  • Currently receiving anabolic steroids, including testosterone preparations, within 28 days prior to treatment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received a matching placebo to AG-348 tablets, for a period of 12 weeks as an optimized dose. This was followed by matching placebo further, for a period of 12 weeks as a fixed-dose.

    Drug: Placebo

  • Experimental
    AG-348, 5 mg

    Participants received AG-348 tablets, 5 milligrams (mg) twice daily (BID), administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 5 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.

    Drug: AG-348

  • Experimental
    AG-348, 20 mg

    Participants received AG-348 tablets, 5 mg BID, administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 20 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.

    Drug: AG-348

  • Experimental
    AG-348, 50 mg

    Participants received AG-348 tablets, 5 mg BID, administered orally, for 4 weeks as a starting dose, followed by two potential sequential dose level increases to 20 mg and 50 mg BID at Weeks 4 and 8 respectively as determined by the investigator based on safety and efficacy. The optimized dose for each participant was determined as 50 mg BID at Week 12, and participants then received that optimized dose for a period of 12 weeks as a fixed dose.

    Drug: AG-348

Interventions

  • DrugPlacebo

    Placebo matching AG-348 tablets, administered to maintain the blind.

  • DrugAG-348

    AG-348 tablets.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Hemoglobin (Hb) Response (HR)

    Hemoglobin response (HR) is defined as a ≥1.5 g/dL (0.93 mmol/L) increase in Hb concentration from baseline that is sustained at 2 or more scheduled assessments at Weeks 16, 20, and 24. The baseline Hb concentration is the average of all available Hb concentrations for a participant during the Screening Period up to the first dose of study treatment. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

    Time frame: Baseline, Weeks 16, 20, 24

Secondary outcomes

  1. Average Change From Baseline in Hb Concentration at Weeks 16, 20 and 24

    This is the change in Hb concentration at Weeks 16, 20 and 24 compared to baseline. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

    Time frame: Baseline, Weeks 16, 20, 24

  2. Maximum Change From Baseline in Hb Concentration

    This is the maximum change from baseline in Hb concentration up to Week 24. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

    Time frame: Baseline, up to Week 24

  3. Time to Achieve an Increase in Hb Concentration of 1.5 g/dL or More

    This is the time taken to first achieve an increase of hemoglobin concentration of 1.5 g/dL or more from baseline. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

    Time frame: Baseline, up to Week 24

  4. Average Change From Baseline in Indirect Bilirubin at Weeks 16, 20 and 24

    The change from baseline in indirect bilirubin levels was summarized. Indirect bilirubin is a marker for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

    Time frame: Baseline, Weeks 16, 20, 24

  5. Average Change From Baseline in Lactic Acid Dehydrogenase (LDH) at Weeks 16, 20 and 24

    The change from baseline in LDH levels was summarized. LDH is a marker for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

    Time frame: Baseline, Weeks 16, 20, 24

  6. Average Change From Baseline in Haptoglobin at Weeks 16, 20 and 24

    The change from baseline in haptoglobin levels was summarized. Haptoglobin levels are markers for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

    Time frame: Baseline, Weeks 16, 20, 24

  7. Average Change From Baseline in Reticulocyte Percentages at Weeks 16, 20 and 24

    The change from baseline in reticulocyte percentage was summarized. Reticulocyte levels are markers for hematopoietic activity. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

    Time frame: Baseline, Weeks 16, 20, 24

  8. Change From Baseline in Pyruvate Kinase Deficiency Diary (PKDD) Score at Week 24

    The PKDD is a 7-item patient reported outcome (PRO) measure of the core signs and symptoms associated with PK deficiency in adults. Participants rate their experience with symptoms of PK deficiency on the present day. The symptoms include those associated with tiredness, jaundice, bone pain, shortness of breath, and energy level. The score ranges from 25 to 76, with higher scores indicating a higher disease burden. The change from baseline in PKDD weekly scores was evaluated. A negative change from baseline indicates a lower disease burden. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

    Time frame: Baseline, Week 24

  9. Change From Baseline in Pyruvate Kinase Deficiency Impact Assessment (PKDIA) Score at Week 24

    The PKDIA is a 12-item patient reported outcome (PRO) measure of the common impacts of PK deficiency on activities of daily living. Participants rate how PK deficiency has impacted aspects of daily living in the past 7 days, including impacts on relationships; perceived appearance; work performance; and leisure, social, mental, and physical activities. The score range is 30 to 76, with higher scores indicating a higher disease burden. The change from baseline in PKDIA scores was evaluated. A negative change from baseline indicates a lower disease burden. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

    Time frame: Baseline, Week 24

  10. Percentage of Participants With Adverse Events

    An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: From signing of informed consent form to the end of study, including follow-up (up to Day 197)

  11. Area Under the Curve From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] for AG-348 at Week 12

    Time frame: Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)

  12. Maximum Plasma Concentration (Cmax) for AG-348

    Time frame: Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)

  13. Time to Cmax (Tmax) for AG-348

    Time frame: Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)

  14. Time to Last Measurable Concentration (Tlast) for AG-348

    Time frame: Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)

  15. Exposure-Response Relationship of Adverse Event (Hot Flush) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters

    Predicted probability of experiencing all grade hot flush at the doses of 5, 20, and 50 mg mitapivat BID based on exposure-response model.

    Time frame: From first dose of mitapivat to the end of study, including follow-up (up to Day 197)

  16. Exposure-Response Relationship Between Safety Parameters (Sex Hormone in Male Subjects) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters

    Predicted percent change from baseline at Week 24 in the sex hormone measures (total testosterone, free testosterone, and estrone) at the doses of 5, 20, and 50 mg mitapivat BID in male participants.

    Time frame: Baseline, Week 24

Other outcomes

  1. Percentage of Participants With Adverse Events of Special Interest (AESI)

    An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AESI can be serious or non-serious.

    Time frame: Through 4 weeks after last dose (approximately Week 31)

  2. Change From Baseline in Bone Mineral Density Z-Score at Week 24

    Time frame: Baseline, Week 24

  3. Change From Baseline in Bone Mineral Density T-Score at Week 24

    Time frame: Baseline, Week 24

07

Results

Posted May 24, 2022

Participant flow

A total of 80 participants were randomized in the study, which was conducted across multiple sites in 14 countries: Brazil, Canada, Denmark, France, Germany, Italy, Japan, Republic of Korea, Netherlands, Spain, Switzerland, Turkey, United Kingdom, and United States. The study was conducted from 9 August 2018 to 9 October 2020.

Participant flow — Overall Study
MilestonePlacebo Comparator: PlaceboExperimental: AG-348 5 mgExperimental: AG-348, 20 mgExperimental: AG-348, 50 mg
Started402335
Completed392335
Not completed1000
Withdrew: Lost to follow-up1000

Outcome measures

PrimaryPercentage of Participants Achieving a Hemoglobin (Hb) Response (HR)

Hemoglobin response (HR) is defined as a ≥1.5 g/dL (0.93 mmol/L) increase in Hb concentration from baseline that is sustained at 2 or more scheduled assessments at Weeks 16, 20, and 24. The baseline Hb concentration is the average of all available Hb concentrations for a participant during the Screening Period up to the first dose of study treatment. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

Time frame:
Baseline, Weeks 16, 20, 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Hemoglobin (Hb) Response (HR)
percentage of participantsPlacebo Comparator: PlaceboExperimental: AG-348
Percentage of Participants Achieving a Hemoglobin (Hb) Response (HR)040.0
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: AG-348 · Exact Cochran-Mantel-Haenszel · p = <0.0001 (2-sided p-value)
SecondaryAverage Change From Baseline in Hb Concentration at Weeks 16, 20 and 24

This is the change in Hb concentration at Weeks 16, 20 and 24 compared to baseline. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

Time frame:
Baseline, Weeks 16, 20, 24
Reported as:
Least squares mean · grams per liter (g/L)
Average Change From Baseline in Hb Concentration at Weeks 16, 20 and 24
grams per liter (g/L)Placebo Comparator: PlaceboExperimental: AG-348
Average Change From Baseline in Hb Concentration at Weeks 16, 20 and 24-1.48 ± 2.08216.73 ± 2.075
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: AG-348 · Mixed-effect Model Repeated Measure · p = <0.0001 · Ls mean difference: 18.21 · 95% CI 12.41 to 24.01Standard error = 2.913
SecondaryMaximum Change From Baseline in Hb Concentration

This is the maximum change from baseline in Hb concentration up to Week 24. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

Time frame:
Baseline, up to Week 24
Reported as:
Mean · g/L
Maximum Change From Baseline in Hb Concentration
g/LPlacebo Comparator: PlaceboExperimental: AG-348
Maximum Change From Baseline in Hb Concentration4.76 ± 4.21723.94 ± 21.367
SecondaryTime to Achieve an Increase in Hb Concentration of 1.5 g/dL or More

This is the time taken to first achieve an increase of hemoglobin concentration of 1.5 g/dL or more from baseline. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

Time frame:
Baseline, up to Week 24
Reported as:
Mean · weeks
Time to Achieve an Increase in Hb Concentration of 1.5 g/dL or More
weeksPlacebo Comparator: PlaceboExperimental: AG-348
Time to Achieve an Increase in Hb Concentration of 1.5 g/dL or More—7.66 ± 4.050
SecondaryAverage Change From Baseline in Indirect Bilirubin at Weeks 16, 20 and 24

The change from baseline in indirect bilirubin levels was summarized. Indirect bilirubin is a marker for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

Time frame:
Baseline, Weeks 16, 20, 24
Reported as:
Least squares mean · micromoles per liter (μmol/L)
Average Change From Baseline in Indirect Bilirubin at Weeks 16, 20 and 24
micromoles per liter (μmol/L)Placebo Comparator: PlaceboExperimental: AG-348
Average Change From Baseline in Indirect Bilirubin at Weeks 16, 20 and 245.10 ± 4.061-21.16 ± 4.228
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: AG-348 · Mixed-effect Model Repeated Measure · p = <0.0001 · Ls mean difference: -26.26 · 95% CI -37.82 to -14.70Standard error = 5.788
SecondaryAverage Change From Baseline in Lactic Acid Dehydrogenase (LDH) at Weeks 16, 20 and 24

The change from baseline in LDH levels was summarized. LDH is a marker for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

Time frame:
Baseline, Weeks 16, 20, 24
Reported as:
Least squares mean · units per litre (U/L)
Average Change From Baseline in Lactic Acid Dehydrogenase (LDH) at Weeks 16, 20 and 24
units per litre (U/L)Placebo Comparator: PlaceboExperimental: AG-348
Average Change From Baseline in Lactic Acid Dehydrogenase (LDH) at Weeks 16, 20 and 24-21.18 ± 16.040-91.99 ± 16.222
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: AG-348 · Mixed-effect Model Repeated Measure · p = 0.0027 · Ls mean difference: -70.81 · 95% CI -115.88 to -25.74Standard error = 22.488
SecondaryAverage Change From Baseline in Haptoglobin at Weeks 16, 20 and 24

The change from baseline in haptoglobin levels was summarized. Haptoglobin levels are markers for hemolysis. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

Time frame:
Baseline, Weeks 16, 20, 24
Reported as:
Least squares mean · g/L
Average Change From Baseline in Haptoglobin at Weeks 16, 20 and 24
g/LPlacebo Comparator: PlaceboExperimental: AG-348
Average Change From Baseline in Haptoglobin at Weeks 16, 20 and 240.012 ± 0.04120.169 ± 0.0408
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: AG-348 · Mixed-effect Model Repeated Measure · p = 0.0079 · Ls mean difference: 0.158 · 95% CI 0.043 to 0.273Standard error = 0.0578
SecondaryAverage Change From Baseline in Reticulocyte Percentages at Weeks 16, 20 and 24

The change from baseline in reticulocyte percentage was summarized. Reticulocyte levels are markers for hematopoietic activity. Data presented represents the value of the change from baseline averaged over Weeks 16, 20 and 24. Baseline was defined as the average of all screening assessments within 45 (42+3) days before randomization for participants randomized and not dosed or before the start of study treatment for participants randomized and dosed. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

Time frame:
Baseline, Weeks 16, 20, 24
Reported as:
Least squares mean · Reticulocyte percentages
Average Change From Baseline in Reticulocyte Percentages at Weeks 16, 20 and 24
Reticulocyte percentagesPlacebo Comparator: PlaceboExperimental: AG-348
Average Change From Baseline in Reticulocyte Percentages at Weeks 16, 20 and 240.0038 ± 0.01390-0.0973 ± 0.01401
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: AG-348 · Mixed-effect Model Repeated Measure · p = <0.0001 · Ls mean difference: -0.1011 · 95% CI -0.1391 to -0.0632Standard error = 0.01904
SecondaryChange From Baseline in Pyruvate Kinase Deficiency Diary (PKDD) Score at Week 24

The PKDD is a 7-item patient reported outcome (PRO) measure of the core signs and symptoms associated with PK deficiency in adults. Participants rate their experience with symptoms of PK deficiency on the present day. The symptoms include those associated with tiredness, jaundice, bone pain, shortness of breath, and energy level. The score ranges from 25 to 76, with higher scores indicating a higher disease burden. The change from baseline in PKDD weekly scores was evaluated. A negative change from baseline indicates a lower disease burden. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Pyruvate Kinase Deficiency Diary (PKDD) Score at Week 24
score on a scalePlacebo Comparator: PlaceboExperimental: AG-348
Change From Baseline in Pyruvate Kinase Deficiency Diary (PKDD) Score at Week 24-2.05 ± 0.976-5.16 ± 0.955
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: AG-348 · Mixed-effect Model Repeated Measure · p = 0.0247 · Ls mean difference: -3.11 · 95% CI -5.80 to -0.41Standard error = 1.352
SecondaryChange From Baseline in Pyruvate Kinase Deficiency Impact Assessment (PKDIA) Score at Week 24

The PKDIA is a 12-item patient reported outcome (PRO) measure of the common impacts of PK deficiency on activities of daily living. Participants rate how PK deficiency has impacted aspects of daily living in the past 7 days, including impacts on relationships; perceived appearance; work performance; and leisure, social, mental, and physical activities. The score range is 30 to 76, with higher scores indicating a higher disease burden. The change from baseline in PKDIA scores was evaluated. A negative change from baseline indicates a lower disease burden. As pre-specified in the protocol, the data for this outcome measure is summarized between the active arm vs the placebo arm (AG-348 5 mg, 20 mg and 50 mg arms are analyzed and reported together in comparison to Placebo).

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Pyruvate Kinase Deficiency Impact Assessment (PKDIA) Score at Week 24
score on a scalePlacebo Comparator: PlaceboExperimental: AG-348
Change From Baseline in Pyruvate Kinase Deficiency Impact Assessment (PKDIA) Score at Week 24-1.39 ± 1.157-4.65 ± 1.123
Statistical analysis
  • Placebo Comparator: Placebo vs Experimental: AG-348 · Mixed-effect Model Repeated Measure · p = 0.0421 · Ls mean difference: -3.25 · 95% CI -6.39 to -0.12Standard error = 1.574
SecondaryPercentage of Participants With Adverse Events

An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
From signing of informed consent form to the end of study, including follow-up (up to Day 197)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsPlacebo Comparator: PlaceboExperimental: AG-348 5 mgExperimental: AG-348 20 mgExperimental: AG-348 50 mg
Percentage of Participants With Adverse Events89.750.010088.6
SecondaryArea Under the Curve From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] for AG-348 at Week 12
Time frame:
Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)
Reported as:
Geometric mean · h*ng/mL
Area Under the Curve From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] for AG-348 at Week 12
h*ng/mLAG-348, 5mgAG-348, 20 mgAG-348, 50mg
Area Under the Curve From Time 0 to the Last Quantifiable Concentration [AUC(0-last)] for AG-348 at Week 12565.9 ± NA1481.2 ± 26.92973.3 ± 35.6
SecondaryMaximum Plasma Concentration (Cmax) for AG-348
Time frame:
Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Maximum Plasma Concentration (Cmax) for AG-348
Nanograms per milliliter (ng/mL)AG-348, 5mgAG-348, 20 mgAG-348, 50mg
Maximum Plasma Concentration (Cmax) for AG-348156.9 ± NA373.1 ± 13.61033 ± 31.2
SecondaryTime to Cmax (Tmax) for AG-348
Time frame:
Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)
Reported as:
Median · hours (h)
Time to Cmax (Tmax) for AG-348
hours (h)AG-348, 5mgAG-348, 20mgAG-348, 50mg
Time to Cmax (Tmax) for AG-3480.75 (0.50 to 1.00)1.02 (0.92 to 2.17)0.50 (0.42 to 1.92)
SecondaryTime to Last Measurable Concentration (Tlast) for AG-348
Time frame:
Pre-dose, 30 minutes and 1, 2, 4 and 8 hours post-dose on Day 85 (Week 12)
Reported as:
Geometric mean · hours (h)
Time to Last Measurable Concentration (Tlast) for AG-348
hours (h)AG-348, 5mgAG-348, 20mgAG-346, 50mg
Time to Last Measurable Concentration (Tlast) for AG-3487.787 ± NA7.809 ± 4.27.162 ± 28.0
SecondaryExposure-Response Relationship of Adverse Event (Hot Flush) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters

Predicted probability of experiencing all grade hot flush at the doses of 5, 20, and 50 mg mitapivat BID based on exposure-response model.

Time frame:
From first dose of mitapivat to the end of study, including follow-up (up to Day 197)
Reported as:
Mean · Percent probability
Exposure-Response Relationship of Adverse Event (Hot Flush) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters
Percent probabilityExperimental: AG-348 5 mgExperimental: AG-348 20 mgExperimental: AG-348 50 mg
Exposure-Response Relationship of Adverse Event (Hot Flush) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters3.37 (1.22 to 7.35)4.03 (1.61 to 8.36)5.5 (2.48 to 10.5)
Other pre-specifiedPercentage of Participants With Adverse Events of Special Interest (AESI)

An AE is any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the study treatment. An AE can, therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AESI can be serious or non-serious.

Time frame:
Through 4 weeks after last dose (approximately Week 31)

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in Bone Mineral Density Z-Score at Week 24
Time frame:
Baseline, Week 24

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in Bone Mineral Density T-Score at Week 24
Time frame:
Baseline, Week 24

Results for this outcome have not been posted.

SecondaryExposure-Response Relationship Between Safety Parameters (Sex Hormone in Male Subjects) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters

Predicted percent change from baseline at Week 24 in the sex hormone measures (total testosterone, free testosterone, and estrone) at the doses of 5, 20, and 50 mg mitapivat BID in male participants.

Time frame:
Baseline, Week 24
Reported as:
Mean · Percent change
Exposure-Response Relationship Between Safety Parameters (Sex Hormone in Male Subjects) and AG-348 Concentration and Relevant AG-348 Pharmacokinetic Parameters
Percent changeExperimental: AG-348 5 mgExperimental: AG-348 20 mgExperimental: AG-348 50 mg
Total Testosterone0.877 (0.41 to 1.43)3.18 (1.49 to 5.4)7.59 (3.29 to 13.7)
Free Testosterone6.01 (1.66 to 13.2)14.1 (4 to 27.5)26 (7.14 to 55.1)
Estrone-31.5 (-51 to -21.1)-56.5 (-67.3 to -48.4)-68.2 (-74.5 to -62.6)

Adverse events

Collected over From time of signing of informed consent form to end of study, including follow-up (up to Day 197). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Comparator: Placebo0/39 (0%)2/39 (5.1%)35/39 (89.7%)
Experimental: AG-348, 5 mg0/2 (0%)0/2 (0%)1/2 (50%)
Experimental: AG-348, 20 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Experimental: AG-348, 50 mg0/35 (0%)3/35 (8.6%)31/35 (88.6%)
Most frequent serious events
Most frequent serious events
EventPlacebo Comparator: PlaceboExperimental: AG-348, 5 mgExperimental: AG-348, 20 mgExperimental: AG-348, 50 mg
Musculoskeletal painMusculoskeletal and connective tissue disorders0/390/21/30/35
GastroenteritisInfections and infestations0/390/20/31/35
Atrial fibrillationCardiac disorders0/390/20/31/35
Rib fractureInjury, poisoning and procedural complications0/390/20/31/35
Metapneumovirus infectionInfections and infestations1/390/20/30/35
Obstructive pancreatitisGastrointestinal disorders1/390/20/30/35
Most frequent other events
Showing 10 of 45
Most frequent other events
EventPlacebo Comparator: PlaceboExperimental: AG-348, 5 mgExperimental: AG-348, 20 mgExperimental: AG-348, 50 mg
NauseaGastrointestinal disorders9/390/22/35/35
DiarrhoeaGastrointestinal disorders7/390/22/32/35
NasopharyngitisInfections and infestations6/390/22/33/35
ArthralgiaMusculoskeletal and connective tissue disorders2/390/22/32/35
GastroenteritisInfections and infestations0/391/20/32/35
DyspepsiaGastrointestinal disorders2/390/21/30/35
DyspnoeaRespiratory, thoracic and mediastinal disorders4/390/21/32/35
FatigueGeneral disorders4/390/21/34/35
HeadacheNervous system disorders13/390/21/35/35
HypertensionVascular disorders0/390/21/31/35

Baseline characteristics

Full analysis set included all participants who were randomized.

Age, Continuous
Age, Continuous(years)Placebo Comparator: PlaceboExperimental: AG-348, 5 mgExperimental: AG-348, 20 mgExperimental: AG-348, 50 mgTotal
Mean37.2 ± 15.9221.5 ± 4.9548.0 ± 26.2135.8 ± 14.0736.6 ± 15.47
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Comparator: PlaceboExperimental: AG-348, 5 mgExperimental: AG-348, 20 mgExperimental: AG-348, 50 mgTotal
Female24022248
Male16211332
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Comparator: PlaceboExperimental: AG-348, 5 mgExperimental: AG-348, 20 mgExperimental: AG-348, 50 mgTotal
Hispanic or Latino10023
Not Hispanic or Latino34122562
Unknown or Not Reported511815
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Comparator: PlaceboExperimental: AG-348, 5 mgExperimental: AG-348, 20 mgExperimental: AG-348, 50 mgTotal
American Indian or Alaska Native00000
Asian30058
Native Hawaiian or Other Pacific Islander00011
Black or African American00000
White32232360
More than one race10001
Unknown or Not Reported400610
08

Study locations

46 sites
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Indiana Hemophilia and Thrombosis Center
    Indianapolis, Indiana 46260, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • The Children's Hospital Corporation d/b/a Boston's Children Hospital
    Boston, Massachusetts 02115, United States
  • Wayne State University School of Medicine, Children's Hospital of Michigan
    Detroit, Michigan 48304, United States
  • Duke University
    Durham, North Carolina 27705, United States
  • East Carolina University
    Greenville, North Carolina 27858, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Houston Methodist Research Institute
    Houston, Texas 77030, United States
  • Primary Children's Hospital Univ. of Utah
    Salt Lake City, Utah 84112, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Hospital Central da Faculdade de Medicina USP Cidade Universitaria
    São Paulo, Brazil
  • McMaster University - Health Sciences Centre
    Hamilton, L8S 4LB, Canada
  • Toronto General Hospital, University Health Network
    Toronto, M5G 2C4, Canada
  • Institute of Hematology and Blood Transfusion
    Prague, Czechia
  • University of Copenhagen, Herlev Hospital
    Herlev, 2730, Denmark
  • CHU Amiens Picardie
    Amiens, 80054, France
  • Hopital Saint-Andre
    Bordeaux, France
  • Hôpital Henri-Mondor
    Créteil, 94010, France
  • Hôpital de la Timone
    Marseille, Cedex 5, 13385, France
  • Institut Claudius Regaud
    Toulouse, France
  • Charite University Medicine
    Berlin, Germany
  • Universitätsklinikum Würzburg
    Würzburg, 97080, Germany
  • Ospedale Galliera
    Genova, 16128, Italy
  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • AOU Policlinico, Università della Campania "Luigi Vanvitelli"
    Napoli, 80138, Italy
  • Tohoku University Hospital
    Sendai-City, Miyagi, Japan
  • Kyoto Katsura Hospital
    Kyoto, Japan
  • Agios Investigative Site
    Mie, Japan
  • Osaka City General Hospital
    Osaka, 534-0021, Japan
  • Kansai Medical University, Department of Pediatrics, Hirakata Hospital
    Osaka, Japan
  • Toho University Omori Medical Center
    Tokyo, Japan
  • Yeungnam University Hospital
    Daegu 705-703, 42415, Korea, Republic of
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584, Netherlands
  • Hospital U. Vall d'Hebron Servicio de Hematología Clínica
    Barcelona, 08035, Spain
  • Hospital Clinico Universitario Virgen de la Arricaxa
    El Palmar, 30120, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Centre Hospitalier Universitaire Vaudois (CHUV)
    Lausanne, 1011, Switzerland
  • Department of Paediatrics and Thalassaemia Center, Faculty of Medicine Siriraj
    Bangkok, 10700, Thailand
  • Hacettepe University
    Ankara, Turkey
  • Addenbrooke's Hospital
    Cambridge, 94609, United Kingdom
  • The Royal Liverpool and Broadgreen University
    Liverpool, L7 8XP, United Kingdom
  • Imperial College Healthcare NHS Trust, Hammersmith Hospital
    London, W12 0NN, United Kingdom
  • University College London
    London, W12 0NN, United Kingdom
  • Manchester Royal Infirmary
    Manchester, M13 9WL, United Kingdom
09

References and documents

Publications

  • Al-Samkari H, Galacteros F, Glenthoj A, Rothman JA, Andres O, Grace RF, Morado-Arias M, Layton DM, Onodera K, Verhovsek M, Barcellini W, Chonat S, Judge MP, Zagadailov E, Xu R, Hawkins P, Beynon V, Gheuens S, van Beers EJ; ACTIVATE Investigators. Mitapivat versus Placebo for Pyruvate Kinase Deficiency. N Engl J Med. 2022 Apr 14;386(15):1432-1442. doi: 10.1056/NEJMoa2116634. PubMed 35417638 ↗
  • Rab MAE, Van Oirschot BA, Kosinski PA, Hixon J, Johnson K, Chubukov V, Dang L, Pasterkamp G, Van Straaten S, Van Solinge WW, Van Beers EJ, Kung C, Van Wijk R. AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. Haematologica. 2021 Jan 1;106(1):238-249. doi: 10.3324/haematol.2019.238865. PubMed 31974203 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Oct 2020, 26 months.

Results were first posted in May 2022, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2018
First posted
Jun 7, 2018
StartActual
Aug 9, 2018
Primary completionActual
Oct 9, 2020
CompletionActual
Oct 9, 2020
Results first posted
May 24, 2022
Last update
May 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03548220
Responsible party
Sponsor
First posted
Jun 7, 2018
Start date
Aug 9, 2018
Primary completion
Oct 9, 2020
Completion
Oct 9, 2020
Results posted
May 24, 2022
Last update
May 24, 2022

Study contacts

Medical Affairs
study chair · Agios Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitapivat

Start the discussion